- Home
- KLIC vs ARQT Comparison
KLIC vs ARQT Comparison
Compare KLIC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLIC
- ARQT
- Stock Information
- Founded
- KLIC 1951
- ARQT 2016
- Country
- KLIC United States
- ARQT United States
- Employees
- KLIC N/A
- ARQT N/A
- Industry
- KLIC Semiconductors
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- KLIC Technology
- ARQT Health Care
- Exchange
- KLIC Nasdaq
- ARQT Nasdaq
- Market Cap
- KLIC 1.7B
- ARQT 1.7B
- IPO Year
- KLIC N/A
- ARQT 2020
- Fundamental
- Price
- KLIC $32.15
- ARQT $13.04
- Analyst Decision
- KLIC Strong Buy
- ARQT Strong Buy
- Analyst Count
- KLIC 4
- ARQT 6
- Target Price
- KLIC $48.00
- ARQT $18.80
- AVG Volume (30 Days)
- KLIC 661.4K
- ARQT 2.2M
- Earning Date
- KLIC 05-06-2025
- ARQT 05-06-2025
- Dividend Yield
- KLIC 2.55%
- ARQT N/A
- EPS Growth
- KLIC N/A
- ARQT N/A
- EPS
- KLIC 0.40
- ARQT N/A
- Revenue
- KLIC $691,079,000.00
- ARQT $212,819,000.00
- Revenue This Year
- KLIC N/A
- ARQT $61.15
- Revenue Next Year
- KLIC $14.33
- ARQT $37.98
- P/E Ratio
- KLIC $81.01
- ARQT N/A
- Revenue Growth
- KLIC N/A
- ARQT 100.03
- 52 Week Low
- KLIC $26.63
- ARQT $6.99
- 52 Week High
- KLIC $53.71
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- KLIC 46.79
- ARQT 40.51
- Support Level
- KLIC $32.22
- ARQT $13.27
- Resistance Level
- KLIC $33.16
- ARQT $14.30
- Average True Range (ATR)
- KLIC 0.78
- ARQT 0.71
- MACD
- KLIC -0.08
- ARQT -0.07
- Stochastic Oscillator
- KLIC 24.23
- ARQT 10.94
About KLIC Kulicke and Soffa Industries Inc.
Kulicke & Soffa Industries Inc is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments which includes Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.